1. Technical Field
The present invention relates to the field of gastric medical devices, and more particularly, to an endoscopic device connectable to the tissues inside the stomach.
2. Discussion of Related Art
Obesity is reaching epidemic proportions in the Western as well as the developing world. Along with the increase in the prevalence of simple obesity, there is a growing population of morbidly obese individuals (BMI>40 kg/m2) as well as super obese ones (BMI>50 kg/m2). As obesity carries increased risk of mortality and a broad spectrum of related co-morbidity, treatment approaches aimed at addressing this problem are needed. The conservative and most successful approach is of lifestyle modifications that include dietary changes and increased physical activity. The problem with this approach is the low compliance achieved and the limited benefit it provides for those with morbid and super obesity. There are several present and emerging pharmacological agents aimed at treating obesity yet their benefit seems to provide a modest and unsustainable weight loss, along with unpleasant side effects, and is diminished upon discontinuation of the drug.
The lack of success of conservative and pharmacological approaches to treat obesity lead to the emergence of bariatric surgery as the most effective and sustainable treatment option. Moreover, some bariatric surgical procedures result in hormonal changes that lead to improvement of conditions such as altered glucose metabolism and thus these procedures are also called “metabolic surgery”.
Bariatric procedures have two general mechanisms of action—restrictive and malapsorptive. The vast majority is performed using a laparoscopic approach and a laparotomy is rarely necessary. The simplest restrictive procedure is gastric banding in which an adjustable elastic band is used to create a small gastric pouch. The radius of the band can be changed using its subcutaneous bladder. Another procedure that is gaining popularity is the sleeve gastrectomy where a large portion of the stomach is resected leaving a narrow “sleeve” with limited volume. This procedure is claimed to have “metabolic” effects via reduction of ghrelin. The classic bariatric procedure is the Rouxen-Y gastric bypass (RYGB). In this procedure a small gastric pouch is created and anastomosed to a distal part of the small bowel while the stomach and duodenum are anastomosed distally. This leaves the proximal part of the small bowel without pancreatic enzymes and bile salts and reduces the area of absorption. Thus, the RYGB combines a restrictive and malapbsorptive component.
All bariatric procedures cause a greater weight loss than conservative approaches yet carry small but significant operative and peri-operative risks. This has lead to attempts to perform these procedures or imitate their effects via less invasive approaches. The simple approach to the gastro-intestinal tract is via the oral route, thus attempts at designing bariatric procedures that are performed using endoscopic machinery are actively pursued. The simplest one is the gastric balloon or other volume occupying devices that limit gastric capacity. These devices have been demonstrated to have a small short term effect on weight yet have significant side effects that have limited their use in clinical practice. Other approaches have attempted to suture the gastric wall using an endoscope thus reducing its volume and thus imitating the gastric sleeve procedure. Yet another approach contemplated a variable outlet that can be changed manually using a laparoscopic or endoscopic mechanism similar to the classic gastric band. Another attempt has been made to combine the restrictive and malabsorptive approach by connecting a flexible tube to the vicinity of the gastro-esophageal junction and leading it via the pylorus through the duodenum for a variable length. This approach creates a limited gastric pouch and adds a “bypass” component.
GERD is a common condition afflicting millions of adults and children that results from an anatomical or regulatory derangement of the gastro-esophageal sphincter that allows reflux of acid gastric contents into the esophagus. This condition is usually treated by pharmacological means and in severe case—by surgical means. There is currently no useful intra-gastric device to address this medical problem.
U.S. Pat. No. 7,037,344 discloses an artificial stoma device, a gastric sleeve device, an intestinal sleeve device and a combined gastrointestinal sleeve device. The following documents disclose various gastric pouches: U.S. Pat. Nos. 4,403,604, 6,981,978, 7,037,344, and 7,267,694, U.S. Patent Publication Nos. 20040122453, 20050267499, 2005240279, 20090012541, 2009093839, and 20100114130.
Embodiments of the present invention provide a medical device comprising an inert tubular adapter comprising a proximal rim arranged to be connectable to an inner lining of the stomach to encircle the esophageal sphincter, the connection characterized by a specified healing period, and a treatment element affixable to the inert tubular adapter and having an operative state arranged to apply a treatment, wherein the medical device has an activated state in which the treatment element is affixed to the adapter and is in the operative state, and an inactive state in which the treatment element is not operative or is not affixed to the adapter, wherein the medical device is arranged to be activated only after a specified period that is equal to or longer than the healing period, to temporally separate the connection of the tubular adapter and the application of the treatment.
These, additional, and/or other aspects and/or advantages of the present invention are: set forth in the detailed description which follows; possibly inferable from the detailed description; and/or learnable by practice of the present invention.
The present invention will be more readily understood from the detailed description of embodiments thereof made in conjunction with the accompanying drawings of which:
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is applicable to other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
For a better understanding of the invention, the term “intake limiting pouch” in the present disclosure is defined in a non-limiting manner as an artificial mechanical structure (unlike common gastric pouches made at least in part from the stomach lining) connected within the stomach and encircling the esophageal sphincter, that receives the intake of food and liquids coming in through the esophageal sphincter, and at least partially holds the intake for a specified period of time, to limit the amount of possible intake in that time. The intake limiting pouch may hold and release the intake, hold and release a part of the intake, or create a mechanical barrier that postpones the transition of the intake from the esophagus to the stomach.
Medical device 100 comprises an inert tubular adapter 110 that is connected to the inner lining 95 of stomach 85, and a treatment element 120 (or parts thereof) that is affixable to inert tubular adapter 110. Treatment element 120 (or parts thereof) has an operative state 122 in which it is arranged to apply a treatment such as turning device 100 to an intake limiting pouch or to an anti-GERD one way valve, or to deliver a drug.
Medical device 100 has an inactive state 101, in which treatment element 120 is not operative or is not affixed to adapter 110, and an activated state 102, in which treatment element 120 is operative (122).
Tubular adapter 110 may have a diameter that is larger than the diameter of sphincter 90 in its maximal opening size, to allow some mechanical freedom to both device 100 and stomach lining 95.
Device 100 uses stomach lining 95 only as an anchoring area, and does not utilize lining 95 build the pouch or any parts of device 100.
Medical device 100 is arranged to be activated only a specified period after the connection of tubular adapter 110 to inner lining 95 of stomach 85. The specified period is equal to or longer than the healing period of the connection itself, to separate temporally the connection of tubular adapter 110 and the application of the treatment.
For example, medical device 100 may be assembled prior to its insertion to stomach 85, inserted and attached endoscopically to inner lining 95, and have a delayed activation mechanism. Alternatively, only adapter 110 may be inserted and attached endoscopically to inner lining 95, and after the specified period, only treatment element 120 may be inserted endoscopically and attached to adapter 110. Treatment element 120 may be operative (122) directly after its attachment to adapter 110, or activation of device 100 may be further delayed by a holding element 130, as described below. Device 100 may be self activated by a mechanical or chemical delayed release mechanism, or activated externally by a signal of any kind. Additionally, treatment element 120 may be replaced endoscopically after or even before a first use upon corresponding indications.
In embodiments, inert tubular adapter 100 may be connected to stomach 85 at an occurring opportunity and stay inert and inactivated for a long period within stomach 85. Treatment element 120 may be operated (122) or connected to adapter 110 at any later occasion.
In contrast to prior art methods and devices, medical device 100 temporally separates the attachment phase from the beginning of treatment, and ensures thereby both proper healing of attachment area 112 before the commencement of the treatment as well as the safety of the associated force application.
During the healing period the patient is not limited in food consumption as the inner passage of the adapter is larger than esophageal sphincter 90. In this way, force application on connection area 112 (sutures or other means of connection) is avoided, and good healing of attachment area 112 is achieved. Hence, in contrast to prior art methods and devices which require supervision and restrictions to food consumption during the healing period, patients treated in the proposed procedures are not limited in regards to food consumption during the healing period. Furthermore, the treating physicians have a better control on the treatment, as device 100 allows a better control on the commencement of the treatment, and also allows temporary or permanent cessation of the treatment by changing the state of treatment element 120 to inoperative, or removing treatment element 120 altogether, without wounding or damaging stomach 85, as adapter 110 may be left connected in stomach 85. Exchanging treatment element 120 may also be carried out endoscopically, without damaging the connection of adapter 110 to stomach 85. Any or both adapter 110 and treatment element 120 may be removed from stomach 85 by a single procedure.
Inert tubular adapter 110 comprises a proximal rim 111 and a distal rim 119. Proximal rim 111 is arranged to be connectable to inner lining 95 of stomach 85, to encircle the esophageal sphincter 90, such that the fluid connection of stomach 85 with esophagus 80 is carried out via device 100.
Proximal rim 111 may be arranged to enable its connection (112) to inner lining 95 of stomach 85 by suturing, gluing, clipping, stapling, and riveting. Riveting may comprise using blind rivets with expanding large caps on the opposite side of the insertion side. Riveting may utilize non-blind rivets. The rivets may be connected to each other on the serosal side of the tissue.
The whole or part of medical device 100 may have an inactive state 101 and an activated state 102, for example a deformation of tubular adapter 110 may participate in the activation of device 100.
Treatment element 120 is affixable to distal rim 119 and has operative state 122 arranged to apply a treatment. Operative state 122 may comprise a mechanical deformation, a position change, a change in chemical character or any other change that affects the stomach or the food passing through device 100.
Tubular adapter 110 may be arranged to receive treatment element 120 after the specified healing period has passed. For example (
In embodiments, treatment element 120 may be affixed to the adapter walls or be embedded within the walls (see below,
Tubular adapter 110 and treatment element 120 may be arranged to be endoscopically inserted into stomach 85 by a single insertion procedure, with treatment element 120 in an inoperative state 121. A transition of treatment element 120 from inoperative state 121 to operative state 122 may be carried out upon a specified condition that takes place after the specified healing period.
Medical device 100 may comprise at least one holding element 130 such as dissolvable elements arranged to change the state of treatment element 120 from inoperative 121 to operative 122, or the state of device 100 from inactive 101 to active 102. The specified condition may be a dissolution of the dissolvable element(s), upon which the transition of treatment element 120 to operative state 122 occurs by a configurational change of medical device 100. The dissolvable elements may comprise a band, a pin or a thread.
Holding element 130 may have a toroidal shape, e.g. be a ring or a band, flexible or stiff or made of surgical suture. Holding element 130 may be arranged to release parts of treatment element 120 by dissolution of dissolvable elements in holding element 130. Holding element 130 may be made of plastic, metal, fabric, shape memory material and their combinations.
Holding element 130 may be associated with the activator that receives an external signal and operates treatment element 120 by cutting or dissolving holding element 130.
For example (
The specified condition may comprise an external signal (e.g. electromagnetic radiation, ultrasound signal, magnetic or electric signal). Treatment element 120 may comprise an activator (not shown) arranged to receive the external signal and activate device 100.
The specified condition may comprise an internal or an external stimulus of physical, mechanical, chemical electric or thermal nature. For example, the stimulus may comprise temperature, and the activation of device 100 may be carried out by drinking a hot fluid. In another example, activation of device 100 may be carried out by drinking a fluid having certain chemical character, such as reactivity with holding element 130, induction of a certain pH level to dissolve holding element 130 etc.
The specified condition may comprise a pre-determined self activation, an exogenously induced activation (such as an external signal detected by an activator, or an induced activation by an administered substance causing e.g. a chemical reaction, a temperature change or an energy supply to device 100) and an endoscopically performed activity (such as cutting holding element 130 to release treatment element 120).
The specified condition may be incorporated into holding element 130 as a chemical or mechanical character that causes activation of device 100 after a specified period. In this case the specified condition is inherent in the structure or composition of holding element 130 or device 100.
Dissolvable element as holding element 130 may be made of PLGA (poly (lactic-co-glycolic acid)), PGA (Polyglycolic acid), Caprolactones and any other known biocompatible and bio-dissolvable materials. The dissolution period of dissolvable element 130, that may partly or fully determine the activation period of device 100, may result from dissolution characteristics of the materials involved or from interaction of these materials with external signals, an internal or external stimulus, or intake liquids. For example, a patient may drink a liquid that promotes the dissolution of dissolvable elements 130, like having chelators that scavenge divalent cations to break dissolvable elements 130, or simply a hot fluid that promotes dissolution of dissolvable elements 130. In embodiments, a mechanical intervention may be used to activate device 100, for example cutting or releasing holding element 130 endoscopically.
To make it more flexible at insertion to stomach 85, holding element 130 may be a flexible tape or yarn made of dissolvable materials. When these materials dissolve at the end of the healing period, e.g. in a week or more, device 100 changes to activated state 102, e.g. taking on a final shape, and performs its therapeutic activity.
Treatment element 120 may comprise flaps that are positioned within tubular adapter 110. Upon activation, device 100 may change it form to constrict the passage of food to the stomach.
Tubular adapter 110 may be made of at least one biocompatible semi-permeable flexible material (e.g. rubber, plastic, metal, carbon and other fibers, or any combination thereof) or non-permeable materials. The structure of tubular adapter 110 may be mesh-like, membranous, or fibrous at different part of adapter 110 or in adapter 110 as a whole. Tubular adapter 110 may have a longitudinally variable flexibility, selected to allow the connection of proximal rim 111 to inner lining 95, to stabilize device 100, to allow a change in a spatial configuration of device 100 upon its transition from inactive 101 to activated 102 state, and to provide a distal support of treatment element 120.
In embodiments of device 100 as an anti-GERD device, such as a one way valve, adapter 110 and treatment element 120 may be made of impermeable material.
The mechanical strength of tubular adapter 110 may change longitudinally (e.g.
Tubular adapter 110 may have a longitudinally variable permeability selected to control fluid exchange between the stomach lumen and an internal volume of adapter 100.
Tubular adapter 110 may comprise a rigid area 113 near proximal rim 111 that attenuates forces acting through tubular adapter 110 on attachment area 112. Rigid area 113 may be ring shaped and arranged to protect attachment area 112 from forces that could be activated by tension in tubular adapter 110 in its activated state 102, e.g. operating as an intake limiting pouch. Area 113 can be made rigid in tension but flexible enough to enable insertion of device 100 via the esophagus.
Treatment element 120 may comprise at least one supportive element 124 that is embedded within a more flexible distal part of tubular adapter 110 (
Supportive elements 124 may comprise rigid beams embedded longitudinally in tubular adapter 110, or one or more rigid tubular elements. The rigid beams may be pivoted on at least one supportive element 126 embedded in tubular adapter 100 (
The distal ends of supportive elements 124 (e.g. rigid thin beams) may be interconnected by an annular element 147, such as a thread yarn or an annular spring, arranged to define a size of distal orifice 123 and to allow an endoscopic manual manipulation of a size of distal orifice 123. Distal orifice 123 may have a constant or an adjustable size. In particular, as illustrated below, a structure of the intake limiting pouch may be arranged to decrease a size of distal orifice 123 as a function of an increasing filled volume of the pouch, and vice versa. Either device 100 as a whole (adapter 110 and treatment element 120) or treatment element 120 alone may function as the intake limiting pouch.
Annular element 147 may function as supportive element 126—to urge supportive elements 124 into place to change the spatial configuration of device 100, e.g. to take the form of an intake limiting pouch in activated state 102. Annular element 147 may have this function in device 100 either in a two part configuration (e.g.
Supportive element 126 may comprise a rigid ring arranged to urge supportive elements 124 into place. Holding element 130 may be arranged to restrain supportive elements 124 (e.g. the rigid beams) in inactive state 101 of device 100, and to release supportive elements 124 to deform device 100 to a form of the intake limiting pouch, or any other active form. Pivot 126 may comprise a rigid ring that urges the rigid beams to deform device 100 into the activated formation.
Supportive elements 124 may be embedded in tubular adapter 110 with a mechanical tendency to bend device 100 inwards, i.e. to change from inoperative state 121 (
Treatment element 120 may further comprise a pivot as supportive element 126 connected to supportive elements 124 and arrange to support a turning movement of supportive elements 124 in respect to pivot 126, to generate a constriction of distal rim 119, controlling the size of orifice 123. Due to the constriction, device 100 takes, in activated state 102 a form of an intake limiting pouch.
Furthermore, the proximal end of at least one supportive element 124 may be effected by the content of tubular adapter 110. For example, as the pouch formed in activated state 102 of device 100 gets fuller, supportive element 124 may increase their turning angle around pivot 126 and so decrease the size of orifice 123 to generate a larger resistance to food movement through device 100 and thereby a feeling of satiation. As a result, when ring 130 dissolves, device 100 turns into an intake limiting pouch with a self-regulating outlet 123.
Outlet orifice 123 that limits the evacuation of food from the pouch into the stomach, may be of fixed size, or be self adjusting that such as to change its outlet area as a function of the fullness of the pouch, namely the fuller the pouch the smaller the exit area and vice-versa—when the pouch is empty the exit area may be larger, back to its original size.
Supportive elements 124 may have a variable elasticity, for example a higher elasticity on their distal end to allow a large range of sizes for orifice 123. Distal end 119 of tubular adapter may have a corresponding elasticity.
In embodiments of device 100 as an intake limiting pouch with distal orifice 123, the size of orifice 123 may be either fixed or decreasing by an increasing filled volume of the pouch. Orifice 123 may be adjustable and /or periodically openable according to specified criteria. At least one supportive element 124 may be flexible and comprise a thread yarn that may be tightened endoscopically if needed to regulate the size of orifice 123. Treatment element 120 may comprise a thread yarn embedded around distal orifice 123 and arranged to allow an endoscopic manual manipulation of a size of distal orifice 123. Treatment element 120 may comprise a distal circumferential spring, arranged to constrict distal orifice 123.
In embodiments, tubular adapter 110 may maintain a cylindrical shape in both inactive 101 and activated 102 states of device 100, while treatment element 120 forms alone the constriction of distal opening or orifice 123 of the formed intake limiting pouch.
For example (
In embodiments, treatment element 120 may form a one way valve arranged to prevent stomach fluid from reaching esophagus 80 (
Treatment element 120 may be an intake limiting pouch (
Treatment element 120 may be attached to tubular adapter 110 either during the insertion of tubular adapter 110 or later, e.g. after the healing has ended. The attachment of treatment element 120 as an intake limiting pouch to tubular adapter 110 may be carried out by rim 131 of treatment element 120 pressed into and held by flange 125 associated with distal rim 119 or by rim 119 itself. Rim 131 of treatment element 120 may be, for example, a toroidal flange, a bayonet, a screw types, a band type, or any flexible connection.
Treatment element 120 may comprise a distal circumferential spring (not shown), arranged to constrict distal orifice 123 of device 100.
Medical device 100 may further comprise a drug delivering element 115 (
In embodiments (
Treatment element 120 may be selected to be attached on a connected adapter 110 at any time after the specified period has passed. Moreover, treatment element 120 may be replaced by with another treatment element 120 (to apply a different or a modified treatment, or to renew an effective treatment element 120) while maintaining adapter 110 connected to stomach 85.
Inert tubular adapter 110 and treatment element 120 may be integrated, and device 100 may be functional in a single part configuration as an intake limiting pouch, as illustrated in
One or more fluid containers 141 (
In another embodiment (
Method 150 comprises the following stages: connecting an inert tubular adapter to an inner lining of the stomach (stage 155) to encircle the esophageal sphincter, the connection characterized by a specified healing period, affixing a treatment element to the inert tubular adapter (stage 160), and operating the treatment element to apply a treatment (stage 165), wherein the operating (stage 165) is carried out a specified period after the connecting (stage 155), the specified period being equal to or longer than the healing period, to temporally separate the connection of the tubular adapter (stage 155) and the application of the treatment (stage 165).
Method 150 may comprise restricting a food intake (stage 185), wherein the treatment is creating a partial or full enclosure of an adapter volume (stage 186), and controllably releasing the food from the enclosure (stage 187).
Method 150 may comprise preventing GERD (stage 190), wherein the treatment is allowing a movement of fluids through the adapter in one direction only (stage 191), namely from the esophagus to the stomach and not in the opposite direction (stage 192).
Method 150 may further comprise delivering a drug (stage 195) to the surroundings of the adapter.
Connecting (stage 155) and affixing (stage 160) may be carried out in a single procedure, and operating (stage 165) may be carried out later, either by a natural (stage 170) or artificial (stage 175) dissolution of a dissolvable element that restrains the treatment element from operating when affixed to the adapter (stage 162), or by an external signal (stage 180). Alternatively, affixing (stage 160) may be carried out in a separate procedure from connecting (stage 155).
Affixing (stage 160) may comprise at least partially embedding the treatment element within the inert tubular adapter (163), or pivoting the treatment element on a distal rim of the inert tubular adapter (164).
Operating (stage 165) may comprise changing a spatial configuration of the adapter (stage 167), e.g. to cause the adapter to take on a pouch form. Method 150 may further comprise controlling a size of a distal orifice of the pouch (stage 188), externally or mechanically according to a degree of fullness of the pouch.
Method 150 may further comprise integrating the adapter and the treatment element to a single device (stage 199).
Method 150 may further comprise selecting a treatment element (stage 157), e.g. as an intake limiting pouch, an anti-GERD device, a drug delivering device etc. according to the clinical status of the patient. Method 150 may further comprise replacing one treatment element with another treatment element (stage 197), while maintaining the adapter connected to the stomach.
In the above description, an embodiment is an example or implementation of the invention. The various appearances of “one embodiment”, “an embodiment” or “some embodiments” do not necessarily all refer to the same embodiments.
Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein in the context of separate embodiments for clarity, the invention may also be implemented in a single embodiment.
Furthermore, it is to be understood that the invention can be carried out or practiced in various ways and that the invention can be implemented in embodiments other than the ones outlined in the description above.
The invention is not limited to those diagrams or to the corresponding descriptions. For example, flow need not move through each illustrated box or state, or in exactly the same order as illustrated and described.
Meanings of technical and scientific terms used herein are to be commonly understood as by one of ordinary skill in the art to which the invention belongs, unless otherwise defined.
While the invention has been described with respect to a limited number of embodiments, these should not be construed as limitations on the scope of the invention, but rather as exemplifications of some of the preferred embodiments. Other possible variations, modifications, and applications are also within the scope of the invention.
Number | Date | Country | Kind |
---|---|---|---|
1103467.5 | Mar 2011 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/IB11/53550 | 8/9/2011 | WO | 00 | 6/27/2013 |
Number | Date | Country | |
---|---|---|---|
61372257 | Aug 2010 | US | |
61472205 | May 2011 | US |